Development
Evaxion Biotech A/S
EVAX
$3.13
$0.5521.32%
NASDAQ
| 09/30/2023 | 06/30/2023 | 12/31/2022 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 2.93M | 2.74M | 2.45M | 2.02M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 5.76M | 5.68M | 6.53M | 6.08M | |
| Operating Income | -5.76M | -5.68M | -6.53M | -6.08M | |
| Income Before Tax | -5.87M | -5.91M | -7.05M | -5.92M | |
| Income Tax Expenses | -194.00K | -225.00K | -173.00K | -175.00K | |
| Earnings from Continuing Operations | -5.68M | -5.68M | -6.87M | -5.74M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -5.68M | -5.68M | -6.87M | -5.74M | |
| EBIT | -5.76M | -5.68M | -6.53M | -6.08M | |
| EBITDA | -5.56M | -5.53M | -6.44M | -6.04M | |
| EPS Basic | -21.00 | -21.00 | -28.54 | -24.00 | |
| Normalized Basic EPS | -1.36 | -1.36 | -1.83 | -1.55 | |
| EPS Diluted | -21.00 | -21.00 | -28.54 | -24.00 | |
| Normalized Diluted EPS | -1.36 | -1.36 | -1.83 | -1.55 | |
| Average Basic Shares Outstanding | 2.70M | 2.71M | 2.41M | 2.39M | |
| Average Diluted Shares Outstanding | 270.30K | 270.60K | 240.80K | 239.10K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |